Shanghai Rendu Biotechnology Co

Shanghai Rendu Biotechnology Co Pre-Tax Margin

The Pre-Tax Profit Margin of Shanghai Rendu Biotechnology Co (688193.SS) as of Nov 20, 2026 is 6.31 %. In the previous year, Pre-Tax Profit Margin was -8.58 % — a change of -173.52% (higher).

Pre-Tax Margin

6.31 %

YoY

-173.52%

Last updated:

Pre-Tax Profit Margin of Shanghai Rendu Biotechnology Co is 2025 6.31 % . Pre-Tax Profit Margin of Shanghai Rendu Biotechnology Co was 2024 -8.58 % . It decreases by -173.52% higher compared to the previous year.

The Shanghai Rendu Biotechnology Co Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-48.51 CNY
Jan 1, 2019
4.04 CNY
Jan 1, 2020
28.11 CNY
Jan 1, 2021
24.78 CNY
Jan 1, 2022
8.78 CNY
Jan 1, 2023
2.90 CNY
Jan 1, 2024
-8.58 CNY
Jan 1, 2025
6.31 CNY
The Shanghai Rendu Biotechnology Co Pre-Tax Margin history
YEARPre-Tax MarginYoY
6.31 %-173.52%
-8.58 %-396.29%
2.90 %-67.01%
8.78 %-64.57%
24.78 %-11.83%
28.11 %+595.09%
4.04 %-108.34%
-48.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Rendu Biotechnology Co Stock analysis

What does Shanghai Rendu Biotechnology Co do? Shanghai Rendu Biotechnology Co., Ltd. generates revenue through the sale of molecular diagnostic tests and medical instruments. The company develops diagnostic reagents using RNA isothermal amplification technology, including respiration series, reproduction series, enterovirus series, and blood-borne diseases series. These products are sold domestically within China, targeting healthcare providers and laboratories that require rapid and accurate diagnostic solutions. The firm's focus on domestic market sales ensures consistent demand for its specialized reagents and instruments. The company's product portfolio includes multiple series of diagnostic reagents designed for specific health conditions, such as respiratory and reproductive health. Medical instruments are also manufactured and sold alongside these reagents. Domestic sales within China form the primary revenue stream, with no mention of international markets or additional product lines. The firm's technology and product offerings cater to the needs of medical professionals seeking efficient diagnostic tools. Shanghai Rendu Biotechnology's business model relies on the domestic market for all product sales, with no indication of export or international partnerships. The company's workforce of 528 full-time employees supports the development, manufacturing, and sales of its diagnostic reagents and instruments. Revenue is derived solely from the sale of these products within China, without any reference to third-party collaborations or additional services. Shanghai Rendu Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Rendu Biotechnology Co stock

Pre-Tax Profit Margin of Shanghai Rendu Biotechnology Co is 6.31 % in 2025.

Pre-Tax Profit Margin of Shanghai Rendu Biotechnology Co changed from -8.58 % to 6.31 %, representing a -173.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Shanghai Rendu Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Shanghai Rendu Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Shanghai Rendu Biotechnology Co

All Key Metrics — Shanghai Rendu Biotechnology Co